Ablynx develops NANOBODY® technology, which enables the creation of new therapeutics and the refinement of existing treatments. The technology utilizes miniature, engineered antibodies derived from camelids, allowing for the design of multi-targeting therapies.

Ablynx

DVLP is building a new infrastructure for drug development by digitizing drug assets, financing, and development workflows to accelerate the process of turning molecules into medicines.

DVLP

Sanofi Ventures is the corporate venture capital arm of Sanofi, a global biopharmaceutical company. It focuses on investing in innovative startups and companies that are developing transformative therapies and technologies across various stages of development. The firm seeks to build a portfolio that aligns with Sanofi's strategic interests and leverages the parent company's expertise to support the growth of its investments.

Sanofi Ventures

ProteoGenix is an antibody production company that offers services including antibody generation, engineering, and production, along with protein production and custom gene synthesis.

Metric
Company Name	Ablynx	DVLP	Sanofi Ventures	ProteoGenix
Symbol
MSH ID	COM:ABLYNX	COM:DVLPMEDICINES	COM:SANOFIVENTURES	SCIENCE:PROTEOGENIX
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals	Pharmaceuticals	Biotechnology
Country	BE	US		FR
Stage
Employee Count
Website	ablynx.com	dvlpmedicines.com	sanofiventures.com	proteogenix.science
LinkedIn		dvlpmedicines
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ABLYNX

Ablynx

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue